FORMULATION OF CURCUMIN NANOSUSPENSION USING BOX-BEHNKEN DESIGN AND STUDY OF IMPACT OF DRYING TECHNIQUES ON ITS POWDER CHARACTERISTICS
Â Objective: The objective of this study was to formulate curcumin nanosuspension (NS) using Box-Behnken design (BBD) and solvent-antisolvent technique to overcome the challenges related to its poor dissolution rate.
Methods: Sodium lauryl sulfate (SLS) and poly vinyl pyrrolidone K-60 (PVPK-60) have been used as a surfactant and polymer, respectively, to stabilize the NS. Ethanol was used as solvent to dissolve curcumin and water was used as antisolvent. The study revealed that SLS to curcumin ratio, PVPK-60 to curcumin ratio, solvent to antisolvent ratio and speed of mixing were the critical parameters that affected particle size and zeta potential of the formulation. Hence, based on Box- BBD, 25 formulations were prepared by varying these critical parameters. The optimized batch of CRM NS was further solidified using spray drying as well as rotary evaporation techniques to have a better insight for selection of solidification process in terms of retention of particle size, charge, flow, dissolution, and stability.
Results: About 39.47 folds decrease in particle size of raw CRM was observed after conversion into NS. Further, about 53.57 and 45.45 folds decrease in particle size was observed after spray drying and rotary evaporation. Both the dried nanoparticles have shown comparatively higher solubility, powder flow, and dissolution rate as that of raw CRM. Powder X-ray diffraction study revealed the formation of amorphous nanoparticles. Accelerated stability study revealed that nanoparticles dried by spray drying were able to retain the properties such as particle size, flow, and dissolution rate as compared to rotary evaporated powders.
Conclusion: It can be concluded that spray drying technique could offer many advantages while loading CRM nanoparticles into tablets for their oral administration.
2. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7(7):1894-900.
3. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976;25(15):1811-2.
4. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: A byproduct from curcumin manufacture. J Agric Food Chem 1999;47(10):4297-300.
5. Apisariyakul A, Vanittanakom N, Buddhasukh D. Antifungal activity of turmeric oil extracted from Curcuma longa (Zingiberaceae). J Ethnopharmacol 1995;49(3):163-9.
6. Itthipanichpong C, Ruangrungsi N, Kemsri W, Sawasdipanich A. Antispasmodic effects of curcuminoids on isolated guinea-pig ileum and rat uterus. J Med Assoc Thai 2003;86 Suppl 2:S299-309.
7. Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Ray C. Screening of Indian plants for biological activity: I. Indian J Exp Biol 1968;6(4):232-47.
8. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus Type-1 integrase by curcumin. Biochem Pharmacol 1995;49(8):1165-70.
9. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41(1):40-59.
10. Mohanty C, Das M, Sahoo SK. Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin. Expert Opin Drug Deliv 2012;9(11):1347-64.
11. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4(6):807-18.
12. Shen L, Ji HF. The pharmacology of curcumin: Is it the degradation products? Trends Mol Med 2012;18(3):138-44.
13. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007;337:299-306.
14. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007;330:155-63.
15. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64(4):353-6.
16. Mishra S, Narain U, Mishra R, Misra K. Design, development and synthesis of mixed bioconjugates of acid-glycine, curcumin-glycine/ alanine and curcumin-glycine-piperic acid and their antibacterial and antifungal properties. Bioorg Med Chem 2005;13(8):1477-86.
17. Available from: http://www.dolcas-biotech.com/products/bcm95/. [Last accessed on 2016 Dec 17].
18. John VD, Kuttan G, Krishnankutty K. Anti-tumour studies of metal chelates of synthetic curcuminoids. J Exp Clin Cancer Res 2002;21(2):219-4.
19. Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem 1993;1(6):415-22.
20. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanomedicine: A road to cancer therapeutics. Curr Pharm Des 2013;19(11):1994-2010. 21. Muller RH, Cornelia MK. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Int J Pharm 2006;62(1):3-16.
22. Singh SK, Vaidya Y, Gulati M, Bhattacharya S, Garg V, Pandey NK. Nanosuspension: Principles, perspectives and practices. Curr Drug Deliv 2016;13(8):1222-46.
23. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol 2004;56(7):827-40.
24. Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009;380:216-2.
25. Cal K, Sollohub K. Spray drying technique. I: Hardware and process parameters. J Pharm Sci 2010;99(2):575-86.
26. Schmid K, Arpagaus C, Friess W. Evaluation of the nano spray dryer B-90 for pharmaceutical applications. Pharm Dev Technol 2011;16(4):287-94.
27. Martin A, Bustamante P, Chun AH. In: Sinko PJ, editor. Physical Pharmacy. USA: Lippincott Williams & Wilkins; 2011.
28. Masters K. Spray Drying, an Introduction to Principles of Operational Practice and Applications. 2nd ed. London: Leonard Hill Books; 1976.
29. Beg S, Katare OP, Saini S, Garg B, Khurana RK, Singh B. Solid self-nanoemulsifying systems of olmesartan medoxomil: Formulation development, micromeritic characterization, in vitro and in vivo evaluation. Powder Technol 2016;294:93-104.
30. Kaur P, Singh SK, Garg V, Gulati M, Vaidya Y. Optimization of spray drying process for formulation of solid dispersion containing polypeptide-k powder through quality by design approach. Powder Technol 2005;284:1-11.
31. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res 1998;15(6):889-96.
32. Mahesh KV, Singh SK, Gulati M. A comparative study of top-down and bottom-up approaches for the preparation of nanosuspensions of glipizide. Powder Technol 2014;256:436-9.
33. Shah SR, Parikh RH, Chavda JR, Sheth NR. Application of plackett-burman screening design for preparing glibenclamide nanoparticles for dissolution enhancement. Powder Technol 2013;235:405-11.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.